Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

Summary

The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.

Timeline

Start

2017-01-26

Primary completion

2017-05-17

Completion

2017-06-02

Outcome

Outcome not reported

Stopped (Business): “Early termination is a sponsor decision. No new safety signal or serious adverse event has been observed.”

Drugs

Indications